26,260 Shares in Revvity, Inc. (NYSE:RVTY) Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB purchased a new position in shares of Revvity, Inc. (NYSE:RVTY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 26,260 shares of the company’s stock, valued at approximately $2,870,000.

Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. bought a new stake in shares of Revvity in the third quarter valued at $1,579,487,000. Ceredex Value Advisors LLC bought a new stake in shares of Revvity in the fourth quarter valued at $108,353,000. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in shares of Revvity in the fourth quarter valued at $33,568,000. Boston Trust Walden Corp bought a new stake in shares of Revvity in the fourth quarter valued at $25,154,000. Finally, KBC Group NV purchased a new position in shares of Revvity in the third quarter valued at $25,301,000. 86.65% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of Revvity stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the completion of the sale, the insider now owns 92,801 shares of the company’s stock, valued at $9,677,288.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.60% of the company’s stock.

Revvity Trading Down 0.6 %

Shares of RVTY stock opened at $101.51 on Friday. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. The business has a 50-day moving average price of $104.66 and a two-hundred day moving average price of $101.46. Revvity, Inc. has a 12-month low of $79.50 and a 12-month high of $132.54. The firm has a market cap of $12.54 billion, a P/E ratio of 18.46, a price-to-earnings-growth ratio of 2.67 and a beta of 1.09.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Thursday, February 1st. The company reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.15 by $0.10. Revvity had a return on equity of 7.41% and a net margin of 25.20%. The firm had revenue of $695.90 million during the quarter. Equities analysts anticipate that Revvity, Inc. will post 4.65 EPS for the current fiscal year.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.28%. Revvity’s dividend payout ratio (DPR) is currently 5.09%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on RVTY shares. UBS Group cut Revvity from a “buy” rating to a “neutral” rating and lifted their price target for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. Raymond James lifted their price target on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. KeyCorp lifted their price target on Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Barclays lifted their price target on Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. Finally, Evercore ISI upgraded Revvity from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $88.00 to $125.00 in a research report on Thursday, January 4th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.91.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.